Clinical Trial

SAD Study of CGB3002 in Healthy Participants

Name: SAD Study of CGB3002 in Healthy Participants — clinical trial record (NCT07660341)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of single ascending IV doses of CGB3002 in healthy participants. CGB3002 is being developed to treat Alzheimer's Disease.

Protocol Amendment History 1 change

critical Recruitment opened 2026-07-09

Trial Details

NCT Number	NCT07660341
Lead Sponsor	ChainGen Biopharma Ltd Collaborators: ChainGen Biopharma (Australia) Pty Ltd
Conditions	Alzheimer s Disease
Enrollment	46 participants
Start Date	2026-06-30
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-08